Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

If that does happen, HER2 inhibitor Enhertu could become the first drug in the antibody-drug conjugate (ADC) class to be delivered subcutaneously – which is a tall order for such a large ...